

Executive Summary

PEEL Therapeutics, Inc. is a USA-Israeli biotech startup delivering evolution-inspired medicine to improve patient lives. The success of PEEL's efforts has allowed the company to rapidly expand its preclinical pipeline to include assets inspired by the evolution of elephants, plants, and humans for the treatment of cancer and a wide range of inflammatory diseases.

PEEL's innovation comes from its unique position at the intersection of nature and technology, where we translate natural discoveries into medicine. PEEL scientists start with molecules and proteins that have originated from millions of years of R&D through evolution and turn these into deliverable drugs.

The current PEEL drug pipeline includes:

- **ASSET #1: Plant derived nanomedicine** for cancer that is significantly more effective and less toxic than approved comparable molecules. PEEL's camptothecin-based small molecule shows >80% survival in preclinical work with childhood solid tumors, with recent efforts now in pancreatic and metastatic colorectal cancer. Pre-IND meeting planned for Q1 FY21.
- **ASSET #2: Neutrophil targeted peptide** for inflammatory diseases based on peptide (small protein) that regulates the immune response in newborns. PEEL's peptide improves survival in mice with sepsis from 0% to over 70% (sepsis = final common pathway and cause of death in COVID-19), with pre-IND meeting for COVID-19 planned in Q4 FY21.
- **ASSET #3: Elephant p53 nanomedicine** for cancer treatment and prevention based on 55 million years of cancer resistance in elephants discovered by Dr. Schiffman and his team (*JAMA 2015*), with ongoing construction and testing of elephant p53 lipid nanoparticle.

The PEEL team remains focused on achieving the milestones necessary to bring these assets to market, while evolution provides a continuous source of opportunities for development of new drugs.

Competitive Advantage. PEEL's team is uniquely positioned to succeed, with exclusive licensing and patents surrounding each asset. PEEL's approach to drug development is based on millions of years of evolution with proven biological success in nature to prevent cancer and inflammation.

The PEEL team includes 15 scientists and drug developers in the USA and Israel with extensive experience in protein engineering, genomics, molecular biology, evolution, nanotechnology, and clinical medicine. PEEL is led by *Dr. Joshua D. Schiffman, MD* (co-founder and CEO), a pediatric oncologist trained at Stanford University and cancer researcher at Huntsman Cancer Institute at the University of Utah. The PEEL team is advised by *Dr. Avi Schroeder, PhD* (co-founder), a chemical engineer, member of the Israel Young Academy of Science, president of the Israel Institute of Chemical Engineers, and head of Targeted Drug Delivery and Personalized Medicine Technologies Laboratory at Technion-Israel Institute of Technology.

The PEEL Board of Directors includes *Dr. Willard Dere, MD*, former Senior Vice President and Chief Medical Officer (CMO) at Amgen, Inc. and current Co-Director of Center for Genomic Medicine, Co-Director of Utah Center for Clinical and Translational Science, & Associate Vice President for Research at the University of Utah, *Dr. John Warnock, PhD*, Co-founder, former CEO/Chairman of Adobe Systems, Inc., inventor of the PDF, and *Mrs. Mary Tolan*, Founder and Co-Managing Partner at Chicago Pacific Founders.

The Current Financing Round will close in Q1 FY21. Details available upon request.